New perspectives in treating high-risk cardiac patients. Rosuvastain and it's perspectives for clinical practice use

被引：0

作者：

Bubnova, M. G. ^{[1
,2
]}

机构：

[1] Fed Agcy High Med Technol, State Res Ctr Prevent Med, Moscow, Russia

[2] IM Sechenov Moscow Med Acad, Moscow, Russia

来源：

CARDIOVASCULAR THERAPY AND PREVENTION | 2007年 / 6卷 / 06期

关键词：

lipid-lowering therapy; statins; rosuvastatin; high risk; low-density lipoprotein cholesterol; target levels;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The review summarizes modern principles of lipid-lowering therapy aimed at cardiovascular event risk reduction. The author describes main patient groups in need for early, aggressive lipid-lowering therapy - predominantly, statin therapy New statin treatment tactics is presented, based on the latest results of recent large-scale clinical trials. The article also contains the results of clinical trials on a new generation statin, rosuvastatin, its lipid-lowering and anti-atherosclerotic effects, its pharmacological features and clinical use perspectives.

引用

页码：75 / 82

页数：8

共 9 条

[1] Practice patterns in treating high-risk patients with hyperlipidemia at a Northeast Tennessee University Clinic
Ismail, HM
Simmons, C
Pfortmiller, D
JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : 31 - 36
[2] Complex and high-risk intervention in indicated patients (CHIP) in contemporary clinical practice
Fujimoto, Yudai
Sakakura, Kenichi
Fujita, Hideo
CARDIOVASCULAR INTERVENTION AND THERAPEUTICS, 2023, 38 (03) : 269 - 274
[3] Complex and high-risk intervention in indicated patients (CHIP) in contemporary clinical practice
Yudai Fujimoto
Kenichi Sakakura
Hideo Fujita
Cardiovascular Intervention and Therapeutics, 2023, 38 : 269 - 274
[4] Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice
Rosinha, Alina
Rabaca, Carlos
Calais, Fernando
Pinto, Joao Moreira
Barreira, Joao Vasco
Fernandes, Ricardo
Ramos, Rodrigo
Fialho, Ana Cristina
dos Reis, Jose Palma
FRONTIERS IN ONCOLOGY, 2024, 13
[5] OSCAR Study lessons - "EpidemiOlogy and treatment of high-riSk patients in real-world ClinicAl pRactice, 2005-2006"
Shalnova, S. A.
Deev, A. D.
CARDIOVASCULAR THERAPY AND PREVENTION, 2007, 6 (01): : 47 - 53
[6] Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice
Montoro, Maria Julia
Pomares, Helena
Coll, Rosa
del Castillo, Teresa Bernal
Tormo, Mar
Jimenez, Ana
Brunet, Salut
Casano, Javier
Oiartzabal, Itziar
Diez-Campelo, Maria
Ramos, Fernando
Romero, Rafael
Salido-Fierrez, Eduardo
Pedro, Carmen
Bargay, Joan
Munoz-Novas, Carolina
Lopez, Rocio
Rafel, Montserrat
Valcarcel, David
LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 679 - 690
[7] The new EuroSCORE II does not improve prediction of mortality in high-risk patients undergoing cardiac surgery: a collaborative analysis of two European centres
Howell, Neil J.
Head, Stuart J.
Freemantle, Nick
van der Meulen, Taco A.
Senanayake, Eshan
Menon, Ashvini
Kappetein, A. Pieter
Pagano, Domenico
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 44 (06) : 1006 - 1011
[8] Fluid administration, vasopressor use and patient outcomes in a group of high-risk cardiac surgical patients receiving postoperative goal-directed haemodynamic therapy: a pilot study
Walker, L. J. C.
Young, P. J.
ANAESTHESIA AND INTENSIVE CARE, 2015, 43 (05) : 617 - 627
[9] Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study
Mullins, C. Daniel
Rattinger, Gail B.
Kuznik, Andreas
Koren, Michael J.
CLINICAL THERAPEUTICS, 2008, 30 : 2204 - 2216

← 1 →